For Your Health

[basserdan]

Another AstraZeneca concern arises...

AstraZeneca may have given U.S. outdated vaccine data, agency says

By Kim Khan
Mar. 23, 2021 3:52 AM

* AstraZeneca (NASDAQ:AZN) may have provided the U.S. outdated information that gave an "incomplete" view about the efficacy of its vaccine, according to the U.S. Data Safety and Monitoring Board.

* "Late Monday, the Data and Safety Monitoring Board (DSMB) notified NIAID, BARDA, and AstraZeneca that it was concerned by information released by AstraZeneca on initial data from its COVID-19 vaccine clinical trial," the National Institute for Allergy and Infectious Diseases, headed by Dr. Anthony Fauci, said in a statement.

* "The DSMB expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data. We urge the company to work with the DSMB to review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible."

* “The last thing this vaccine needs is more concern when we kind of thought we were at that point now where we’d put to bed all the other concerns, and then a new one pops up the same day,” Paul Griffin, an associate professor of medicine at the University of Queensland, told Bloomberg.

* The European Medicines Agency issued a statement last week that the benefits of the vaccine still outweigh the risks, despite the link to "rare blood clots with low blood platelets."

* AstraZeneca shares rose 4% yesterday after U.S. trial data showed a 79% efficacy rate.

https://seekingalpha.com/news/3675069-astrazeneca-may-have-given-us-outdated-data-agency-says